Condition: Metastatic Colorectal Cancer · Sponsor: Novartis Pharmaceuticals
The purpose of this study is to evaluate the preliminary efficacy and safety of NIS793 and other novel investigational combinations with standard of care (SOC) anti-cancer therapy vs SOC anti-cancer therapy for the second line treatment of mCRC. This study aims to explore whether different mechanisms of action may reverse resistance and improve responsiveness to the currently considered SOC anti-cancer therapy in the second line metastatic colorectal cancer (mCRC) setting.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| The Angeles Clinic and Research Institute | Los Angeles, California, United States | — |
| University of Michigan Medical | Ann Arbor, Michigan, United States | — |
| WA Uni School Of Med | St Louis, Missouri, United States | — |
| Astera Cancer Center | East Brunswick, New Jersey, United States | — |
| Sarah Cannon Research Institute | Nashville, Tennessee, United States | — |
| Uni Of TX MD Anderson Cancer Cntr | Houston, Texas, United States | — |
| Mays Cancer Center | San Antonio, Texas, United States | — |
| Novartis Investigative Site | Adelaide, South Australia, Australia | — |
| Novartis Investigative Site | Bendigo, Victoria, Australia | — |
| Novartis Investigative Site | Perth, Western Australia, Australia | — |
| Novartis Investigative Site | Brussels, Belgium | — |
| Novartis Investigative Site | Brussels, Belgium | — |
+ 43 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04952753